Due to the absence of HER2 and hormonal ER and PR receptors, hormonal therapy that is effective in other subtypes of breast cancer is not applicable to TNBC, necessitating chemotherapy, which is presently the backbone of systemic treatment [21]. This evidence concerns the gene ERBB2 and breast carcinoma.